


PRODUCT INFORMATION



DCPIB

Item No. 34064

CAS Registry No.: 82749-70-0
Formal Name: 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy]-butanoic acid
MF: C₂₂H₂₈Cl₂O₄
FW: 427.4
Purity: ≥98%
UV/Vis.: λ_{max}: 225, 272 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DCPIB is supplied as a crystalline solid. A stock solution may be made by dissolving the DCPIB in the solvent of choice, which should be purged with an inert gas. DCPIB is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of DCPIB in these solvents is approximately 30 mg/ml.

DCPIB is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, DCPIB should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. DCPIB has a solubility of approximately 0.20 mg/ml in a 1:4 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

DCPIB is an inhibitor of volume-regulated anion channels (VRAC).¹ It inhibits the swelling-induced chloride current ($I_{Cl,swell}$) in bovine pulmonary artery endothelial cells ($IC_{50} = 4.1 \mu M$). DCPIB inhibits the VRAC subunit leucine-rich containing 8A (LRRC8A; $IC_{50} = 20.9 \mu M$) and inhibits sphingosine-1-phosphate-induced cGAMP uptake by LRRC8A in telomerase-immortalized human microvascular endothelial (TIME) cells when used at a concentration of $20 \mu M$.^{2,3} It also inhibits the two-pore domain potassium channels $K_{2p18.1}/TRESK$, $K_{2p3.1}/TASK1$, and $K_{2p9.1}/TASK3$ in COS-7 cells expressing the human channels (IC_{50} s = 0.14, 0.95, and $50.72 \mu M$, respectively).⁴ DCPIB ($10 \mu M$) activates $K_{2p2.1}/TREK1$ and $K_{2p4.1}/TRAAK$ channels in COS-7 cells expressing the human channels. Intracisternal administration of DCPIB ($20 \mu g/kg$) reduces infarct area and neurological deficit scores in a rat model of cerebral ischemia induced by middle cerebral artery occlusion (MCAO).⁵

References

1. Decher, N., Lang, H.J., Nilius, B., *et al. Br. J. Pharmacol.* **134**(7), 1467-1479 (2001).
2. Qiu, Z., Dubin, A.E., Mathur, J., *et al. Cell* **157**(2), 447-458 (2014).
3. Lahey, L.J., Mardjuki, R.E., Wen, X., *et al. Mol. Cell.* **80**(4), 578-591 (2020).
4. Lv, J., Liang, Y., Zhang, S., *et al. ACS Chem. Neurosci.* **10**(6), 2786-2793 (2019).
5. Zhang, Y., Zhang, H., Feustel, P.J., *et al. Exp. Neurol.* **210**(2), 514-520 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM